Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: An absolute contraindication?
作者信息
Haddad Issa, Agarwal Priyal, Hassanein Mohamed
机构信息
Department of Internal Medicine, Michigan State University, Lansing, MI, USA.
Department of Nephrology, University of Mississippi Medical Center, Jackson, MS, USA.
出版信息
Ther Apher Dial. 2022 Aug;26(4):850-851. doi: 10.1111/1744-9987.13833. Epub 2022 Mar 16.
Abstract
摘要
相似文献
1
Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: An absolute contraindication?
Ther Apher Dial. 2022 Aug;26(4):850-851. doi: 10.1111/1744-9987.13833. Epub 2022 Mar 16.
2
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
J Antimicrob Chemother. 2021 Feb 11;76(3):825-827. doi: 10.1093/jac/dkaa500.
3
Liver and kidney function in patients with Covid-19 treated with remdesivir.
Br J Clin Pharmacol. 2021 Nov;87(11):4450-4454. doi: 10.1111/bcp.14831. Epub 2021 May 4.
4
The COVID-19 pandemic: consequences for nephrology.
Nat Rev Nephrol. 2021 Feb;17(2):81-82. doi: 10.1038/s41581-020-00381-4.
5
Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD.
Infect Disord Drug Targets. 2022;22(3):e011221198456. doi: 10.2174/1871526521666211201112410.
6
Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir.
Nefrologia (Engl Ed). 2023 Dec;43 Suppl 2:112-113. doi: 10.1016/j.nefroe.2022.07.008. Epub 2023 Jan 25.
7
Remdesivir in The Treatment of COVID-19.
Am J Nurs. 2021 Jan 1;121(1):55. doi: 10.1097/01.NAJ.0000731668.01845.8c.
8
A Potential Antiviral Treatment for COVID-19: Remdesivir.
Clin Nurse Spec. 2020 Nov/Dec;34(6):257-260. doi: 10.1097/NUR.0000000000000549.
9
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
10
Early remdesivir treatment in COVID-19: Why wait another day?
J Med Virol. 2021 Jul;93(7):4078-4080. doi: 10.1002/jmv.26792. Epub 2021 Feb 1.
本文引用的文献
1
Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study.
Ren Replace Ther. 2021;7(1):59. doi: 10.1186/s41100-021-00378-0. Epub 2021 Oct 21.
2
Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.
Kidney Int Rep. 2021 Mar;6(3):586-593. doi: 10.1016/j.ekir.2020.12.003. Epub 2020 Dec 18.
3
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
J Antimicrob Chemother. 2021 Feb 11;76(3):825-827. doi: 10.1093/jac/dkaa500.
4
A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.02290-20.
Zotero 插件